A large multicentre analysis of CTGF −945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype
- 1 October 2009
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 68 (10) , 1618-1620
- https://doi.org/10.1136/ard.2008.100180
Abstract
Objective: To conduct a replication study to investigate whether the −945 CTGF genetic variant is associated with systemic sclerosis (SSc) susceptibility or specific SSc phenotype. Methods: The study population comprised 1180 patients with SSc and 1784 healthy controls from seven independent case–control sets of European ancestry (Spanish, French, Dutch, German, British, Swedish and North American). The −945 CTGF genetic variant was genotyped using a Taqman 5′ allelic discrimination assay. Results: An independent association study showed in all the case–control cohorts no association of the CTGF −945 polymorphism with SSc susceptibility. These findings were confirmed by a meta-analysis giving a pooled OR = 1.12 (95% CI 0.99 to 1.25), p = 0.06. Investigation of the possible contribution of the −945 CTGF genetic variant to SSc phenotype showed that stratification according to SSc subtypes (limited or diffuse), selective autoantibodies (anti-topoisomerase I or anticentromere) or pulmonary involvement reached no statistically significant skewing. Conclusion: The results do not confirm previous findings and suggest that the CTGF −945 promoter polymorphism does not play a major role in SSc susceptibility or clinical phenotype.Keywords
This publication has 15 references indexed in Scilit:
- Faculty Opinions recommendation of CTGF polymorphism associated with systemic sclerosis.Published by H1 Connect ,2008
- Genetics and Genomic Studies in Scleroderma (Systemic Sclerosis)Rheumatic Disease Clinics of North America, 2008
- A Polymorphism in theCTGFPromoter Region Associated with Systemic SclerosisNew England Journal of Medicine, 2007
- Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblastsPublished by Elsevier ,2007
- Genetic association studiesThe Lancet, 2005
- N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in sclerodermaQJM: An International Journal of Medicine, 2005
- An increased transforming growth factor β receptor type I:Type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase‐deficient transforming growth factor β receptor type II in sclerodermaArthritis & Rheumatism, 2004
- Cyclic Nucleotide-Gated Ion ChannelsAnnual Review of Cell and Developmental Biology, 2003
- Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common diseaseNature Genetics, 2003
- Preliminary criteria for the classification of systemic sclerosis (scleroderma)Arthritis & Rheumatism, 1980